171 related articles for article (PubMed ID: 35934625)
21. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review.
van den Bergh RC; Ahmed HU; Bangma CH; Cooperberg MR; Villers A; Parker CC
Eur Urol; 2014 Jun; 65(6):1023-31. PubMed ID: 24491309
[TBL] [Abstract][Full Text] [Related]
22. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
[TBL] [Abstract][Full Text] [Related]
23. Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis.
Rajwa P; Pradere B; Quhal F; Mori K; Laukhtina E; Huebner NA; D'Andrea D; Krzywon A; Shim SR; Baltzer PA; Renard-Penna R; Leapman MS; Shariat SF; Ploussard G
Eur Urol; 2021 Nov; 80(5):549-563. PubMed ID: 34020828
[TBL] [Abstract][Full Text] [Related]
24. Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes.
Imnadze M; Sjoberg DD; Vickers AJ
Eur Urol; 2016 Jan; 69(1):143-8. PubMed ID: 25913389
[TBL] [Abstract][Full Text] [Related]
25. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.
Chade DC; Eastham J; Graefen M; Hu JC; Karnes RJ; Klotz L; Montorsi F; van Poppel H; Scardino PT; Shariat SF
Eur Urol; 2012 May; 61(5):961-71. PubMed ID: 22280856
[TBL] [Abstract][Full Text] [Related]
26. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
27. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer.
Thomsen FB; Røder MA; Jakobsen H; Langkilde NC; Borre M; Jakobsen EB; Frey A; Lund L; Lunden D; Dahl C; Brasso K
Clin Genitourin Cancer; 2019 Aug; 17(4):e814-e821. PubMed ID: 31196798
[TBL] [Abstract][Full Text] [Related]
28. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
Moldovan PC; Van den Broeck T; Sylvester R; Marconi L; Bellmunt J; van den Bergh RCN; Bolla M; Briers E; Cumberbatch MG; Fossati N; Gross T; Henry AM; Joniau S; van der Kwast TH; Matveev VB; van der Poel HG; De Santis M; Schoots IG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TB; Rouvière O
Eur Urol; 2017 Aug; 72(2):250-266. PubMed ID: 28336078
[TBL] [Abstract][Full Text] [Related]
29. Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach.
Timilshina N; Alibhai SMH; Tomlinson G; Sander B; Cheung DC; Finelli A
J Urol; 2023 Mar; 209(3):540-548. PubMed ID: 36475730
[TBL] [Abstract][Full Text] [Related]
30. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
31. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
[TBL] [Abstract][Full Text] [Related]
32. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
[TBL] [Abstract][Full Text] [Related]
33. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
[TBL] [Abstract][Full Text] [Related]
34. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
35. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
36. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.
Stavrinides V; Giganti F; Trock B; Punwani S; Allen C; Kirkham A; Freeman A; Haider A; Ball R; McCartan N; Whitaker H; Orczyk C; Emberton M; Moore CM
Eur Urol; 2020 Sep; 78(3):443-451. PubMed ID: 32360049
[TBL] [Abstract][Full Text] [Related]
37. Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis.
Rajwa P; Pradere B; Mori K; Ploussard G; Leapman MS; Shariat SF
J Urol; 2021 Jun; 205(6):1559-1568. PubMed ID: 33683937
[TBL] [Abstract][Full Text] [Related]
38. Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.
Musunuru HB; Yamamoto T; Klotz L; Ghanem G; Mamedov A; Sethukavalan P; Jethava V; Jain S; Zhang L; Vesprini D; Loblaw A
J Urol; 2016 Dec; 196(6):1651-1658. PubMed ID: 27569437
[TBL] [Abstract][Full Text] [Related]
39. The Significance of Primary Biopsy Gleason 5 in Patients with Grade Group 5 Prostate Cancer.
Tilki D; Würnschimmel C; Preisser F; Graefen M; Huland H; Mandel P; Tennstedt P
Eur Urol Focus; 2020 Mar; 6(2):255-258. PubMed ID: 32033909
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]